Next on tap for Meridian Bioscience‘s (NASDAQ:VIVO) illumigene molecular diagnostic testing platform is a test for Mycoplasma pneumonia, an infection of the lungs. The illumigene Mycoplasma test is ...

Diagnostic test kit maker Meridian Bioscience (VIVO) has won the approval of the U.S. Food and Drug Administration (:FDA) for its new test for detection of Legionnaire’s disease (legionellosis), a ...

illumigene® Malaria is more widely used than it was a year ago, but Meridian Bioscience says even more countries should use it." Researchers in Europe and philanthropists in New York are singing the ...

Meridian Bioscience Inc. (NASDAQ:VIVO) has obtained a license to begin selling its illumigene C. difficile molecular test in Canada. C. difficile is a bacterium that can cause symptoms ranging from ...

Newtown-based Meridian Bioscience is deploying its newly developed test illumigene® Malaria in Dakar, Senegal and planning a rollout of this potentially life-saving diagnostic across Africa. A test ...

Meridian Bioscience Inc (NASDAQ: VIVO) has agreed to acquire the North American BreathTek business from Otsuka America Pharmaceutical Inc for $20 million in cash. The transaction will close in ...